La Jolla, California -- Pharmaceutical firm Orexigen Therapeutics has received $165 million in venture capital equity and debt, according to an SEC regulatory filing.
Orexigen is developing what it says is a "more effective way to achieve and sustain weight loss through a combined, to drug approach."
Its lead product is Contrave extended release tablets. The medication has several safety cautions and includes serious side effects such as suicidal thoughts or actions.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
A total of 21 investors participated in the financing.
The company is still seeking $165 million in additional financing, according to the filing.